These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

654 related items for PubMed ID: 24351072

  • 21. Clinical and metabolic characteristics of Turkish adolescents with polycystic ovary syndrome.
    Ates S, Aydın S, Ozcan P, Soyman Z, Gokmen Karasu AF, Sevket O.
    J Obstet Gynaecol; 2018 Feb; 38(2):236-240. PubMed ID: 28920502
    [Abstract] [Full Text] [Related]

  • 22. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
    Unfer V, Carlomagno G, Dante G, Facchinetti F.
    Gynecol Endocrinol; 2012 Jul; 28(7):509-15. PubMed ID: 22296306
    [Abstract] [Full Text] [Related]

  • 23. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
    Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G.
    N Engl J Med; 1999 Apr 29; 340(17):1314-20. PubMed ID: 10219066
    [Abstract] [Full Text] [Related]

  • 24. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
    Koo YA, Shin SY, Yoon BK, Choi D.
    Gynecol Endocrinol; 2007 Apr 29; 23(8):461-7. PubMed ID: 17852414
    [Abstract] [Full Text] [Related]

  • 25. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome.
    Dinicola S, Chiu TT, Unfer V, Carlomagno G, Bizzarri M.
    J Clin Pharmacol; 2014 Oct 29; 54(10):1079-92. PubMed ID: 25042908
    [Abstract] [Full Text] [Related]

  • 26. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction.
    Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, Marelli G, Cino I, Redaelli A, Ferrari A.
    Gynecol Endocrinol; 2007 Dec 29; 23(12):700-3. PubMed ID: 17952759
    [Abstract] [Full Text] [Related]

  • 27. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
    Nordio M, Proietti E.
    Eur Rev Med Pharmacol Sci; 2012 May 29; 16(5):575-81. PubMed ID: 22774396
    [Abstract] [Full Text] [Related]

  • 28. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios.
    Nordio M, Basciani S, Camajani E.
    Eur Rev Med Pharmacol Sci; 2019 Jun 29; 23(12):5512-5521. PubMed ID: 31298405
    [Abstract] [Full Text] [Related]

  • 29. Menstrual dysfunction in polycystic ovary syndrome: association with dynamic state insulin resistance rather than hyperandrogenism.
    Ezeh U, Ezeh C, Pisarska MD, Azziz R.
    Fertil Steril; 2021 Jun 29; 115(6):1557-1568. PubMed ID: 33602559
    [Abstract] [Full Text] [Related]

  • 30. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome.
    Zacchè MM, Caputo L, Filippis S, Zacchè G, Dindelli M, Ferrari A.
    Gynecol Endocrinol; 2009 Aug 29; 25(8):508-13. PubMed ID: 19551544
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS).
    Januszewski M, Issat T, Jakimiuk AA, Santor-Zaczynska M, Jakimiuk AJ.
    Ginekol Pol; 2019 Aug 29; 90(1):7-10. PubMed ID: 30756365
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action.
    De Cicco S, Immediata V, Romualdi D, Policola C, Tropea A, Di Florio C, Tagliaferri V, Scarinci E, Della Casa S, Lanzone A, Apa R.
    Gynecol Endocrinol; 2017 Sep 29; 33(9):698-701. PubMed ID: 28434274
    [Abstract] [Full Text] [Related]

  • 38. Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open-label study.
    Kachhawa G, Senthil Kumar KV, Kulshrestha V, Khadgawat R, Mahey R, Bhatla N.
    Int J Gynaecol Obstet; 2022 Aug 29; 158(2):278-284. PubMed ID: 34624138
    [Abstract] [Full Text] [Related]

  • 39. [Evaluation of the myo-inositol-monacolin K association on hyperandrogenism and on the lipidic metabolism parameters in PCOS women].
    Musacchio MC, Cappelli V, Di Sabatino A, Morgante G, De Leo V.
    Minerva Ginecol; 2013 Feb 29; 65(1):89-97. PubMed ID: 23412023
    [Abstract] [Full Text] [Related]

  • 40. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T, Dehghan-Kooshkghazi M.
    Gynecol Endocrinol; 2003 Feb 29; 17(1):51-6. PubMed ID: 12724019
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.